Teva pharmaceuticals has issued a voluntary recall of one lot of its reflux medication after discovering that bottles contained tablets of a drug used to treat fluid retention. The recall affects lot ...

Despite the popularity of generic and biosimilar drugs in Europe—the latter of which have struggled to catch on in the ...

Am J Health Syst Pharm. 2012;69(2):116-124. The clonidine patch is one example of a TDDS offering several of those benefits. Clonidine patches are applied once every seven days, allowing a reduced ...

f Telephone communication with Erika M, medical information department, Teva Pharmaceuticals, 2011 May 26. g Telephone communication with Lori Stone, medical information department, King ...

The guidelines focuse on two weight management medications that have shown superior effectiveness: semaglutide (a GLP-1 receptor agonist) and tirzepatide (a GLP-1/GIP receptor agonist).

Middlesex County Popular ‘miracle’ weight loss drug is causing people to lose their vision, lawsuits claim Published: Jun. 19, 2025, 11:00 a.m.

During this hurricane season and for those to come, DePaul Community Health Center officials say they are making patients’ health and overall wellness a priority. Adequate and affordable ...

Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical (Fosun Pharma) have announced a strategic partnership focused on developing a drug candidate currently in phase 1 clinical development ...

[READ: Exercising on GLP-1s: How to Stay Safe and Healthy] Weight Loss Drugs and Long-Term Success When treating obesity, success isn’t all about losing weight.

The medication was apparently distributed to three states: Illinois, Mississippi, and Pennsylvania. Icosapent ethyl can be “used together with a proper diet to help control high triglyceride (fat-like ...

From the midpoint of 2015 through late 2023, Teva stock lost close to 90% of its value due to a number of headwinds: Its blockbuster multiple sclerosis drug Copaxone lost its sales exclusivity.

Teva and Fosun Pharma join forces to develop TEV-56278, a promising cancer therapy. Read more here.